Objective: The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3.
P
ancreatic neuroendocrine neoplasms (pNENs) are classified, according to the World Health Organization (WHO) classification, 1 in 3 different categories: neuroendocrine tumor G1 (NET G1), NET G2, neuroendocrine carcinoma G3 (NEC G3). This classification is mainly based on the Ki67 value on tumor cells, that is, 2% or less in NET G1, 3% to 20% in NET G2, and greater than 20% in NEC G3. It is well known that Ki67 is a major factor affecting tumor behavior and patients' prognosis in pNENs, 2, 3 thus resulting a key factor when approaching therapeutic strategies for these patients.
In general, pNENs are considered rare diseases, with an overall incidence of 0.3 new cases per 100,000, as reported by the Surveillance Epidemiology and End Results program registries in the United States. 4 Pancreatic NECs (pNECs) G3 are even rarer, being approximately 7% of them. 3 They are considered the most aggressive type of pNENs, with an estimated median overall survival (OS) of 15 months. 3, 5 In this subgroup of patients, both the European Neuroendocrine Tumors Society (ENETS) 6 and the North American Neuroendocrine Tumor Society 7 recommend using first-line systemic chemotherapy (usually based on cisplatin and etoposide) as the standard treatment, when surgical resection is not feasible. However, poor results have been reported by using this approach, with median progression-free survival (PFS) values ranging between 4 and 9 months. 8 Results from second-line approaches are even more disappointing, because median PFS values remain less than 6 months with different chemotherapeutic combinations. 8 It has been recently suggested that NEC G3 category constitutes a heterogeneous group of diseases, including both welldifferentiated and poorly differentiated tumors, which may be considered distinct diseases in terms of clinicopathologic and molecular characteristics, 9 with different implications in terms of patients' prognosis and therapeutic approach. 10, 11 This figure is in line with the conclusions of the Nordic NEC study, 5 which reported a different response to platinum-based therapy in a large series of NEC G3, as well as a different survival when patients were classified according to the Ki67 cutoff level of 55%, as also suggested by another experience. 12 Based on these findings, it is reasonable not to consider NECs G3 as single disease entities, because they show different clinical behavior and response to chemotherapy, depending on tumor morphology, and Ki67 value.
Everolimus (Afinitor; Novartis, Basel, Switzerland) is approved for the treatment of advanced, well-or moderately differentiated pNENs, 13 based on the findings of the RADIANT-3 trial, 14 which reported a significant prolongation in PFS versus placebo. Unfortunately, because the inclusion criteria of that trial were based on morphology, no data are available in the subgroup analysis, depending on Ki67 value.
Recently, everolimus demonstrated some antitumor activity in preclinical models of high-grade gastroenteropancreatic NECs. 15 Interestingly, it has been shown that high levels of phospho-mTOR are frequently detected in aggressive NENs with poorly differentiated morphology, 16 thus supporting the hypothesis for using mTOR pathway inhibition as a possible treatment for this disease.
However, data about everolimus efficacy in a clinical setting of NEC G3 tumors are very limited, because only few single case reports have been published so far. [17] [18] [19] The aim of the present study was to investigate the efficacy of everolimus treatment in a subgroup of patients with pNEC G3, well-or moderately differentiated morphology, and Ki67 less than 55%. treated, then a unique computerized data sheet was created, and data were analyzed retrospectively.
Patients included in the present study had histologically documented, unresectable, progressive stage IV pNEC according to the WHO 2010 classification and ENETS staging system, 1, 20 with tumor morphology identified as well or moderately differentiated, in line with the WHO 2000 classification, 21 and Ki67 between 20% and 55%. The Ki67 proliferative index was expressed as a percentage based on the count of Ki67-positive cells in 2000 tumor cells in areas of the highest immunostaining by manual cell counting. 22 In Italy, it is possible to treat patients having these characteristics with everolimus on label because it was approved by the European Medicines Agency 12 and the Italian Medicines Agency. 23 Although this study had a retrospective design (i.e., the follow-up program was not fully standardized), computed tomography or magnetic resonance imaging assessments were performed before commencing treatment and every 2 to 3 months thereafter according to the ENETS guidelines. 24 Response to treatment was evaluated according to Response Evaluation Criteria In Solid Tumors (RECIST 1.0). 25 Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events version 3.0. 26 All patients provided full informed consent before starting everolimus treatment, according to the regulatory agency rules and local ethics committees.
As usual, PFS was defined as the interval between beginning of treatment and disease progression, or death from any cause, whichever occurred first. Overall survival was defined as the time between start of treatment and death, regardless of the cause.
Both PFS and OS analyses were assessed by the KaplanMeier method. The distribution of continuous variables was reported as median and range.
RESULTS
Data of a total of 15 patients with stage IV pNEC G3 tumors with well-or moderately differentiated morphology treated with everolimus at a 10-mg daily dose were collected from the participating centers and included in the present study. Patients' general features are summarized in Table 1 . Median Ki67 value was 30% (range, 22%-55%). Histological diagnosis was obtained by surgical or bioptic sampling in 7 patients (46.7%) and 8 patients (53.3%), respectively. Eastern Cooperative Oncology Group performance status was 0 in 11 patients (73.3%), and 1 in the remaining 4 patients (26.7%). Tumors expressed somatostatin receptors in all but 1 patient, as confirmed by positive 68 Ga-DOTATOC positron emission tomography or Octreoscan. All but 1 patient had positive 18 F-fluorodeoxyglucose positron emission tomography scans. All patients had distant metastases, which were located in the liver in 14 patients (93.3%), in the bones in 3 patients (20%), in the distant nodes in 3 patients (20%), and in the peritoneum in 1 patient (6.7%). Seven patients (46.7%) had undergone surgery before beginning everolimus.
Overall, 4 patients (26.7%) received everolimus as firstline approach, whereas the remaining 11 patients (73.3%) had been pretreated with first-line platinum-based chemotherapy (5 patients, 33.3%), peptide receptor radionuclide therapy (PRRT) (4 patients, 26.7%), and capecitabine plus temozolomide (2 patients, 13.3%). All but 1 patient also received somatostatin analogs, in combination with everolimus.
Median PFS after everolimus initiation was 6 months (Fig. 1 ). All but 2 patients had undergone disease progression at time of data collection. Median OS after everolimus initiation was 28 months (Fig. 2) . A total of 5 patients died because of disease progression during a median follow-up of 15 months, thus resulting in a mortality rate of 33.3%. A total of 6 patients (40%) maintained response to therapy, defined as stable disease, for at least 12 months after everolimus initiation.
As far as safety is concerned, 9 patients (66.6%) developed AEs, which were grade 3 to 4 in 4 patients (26.7%) (diarrhea, 1 patient; infection, 1 patient; stomatitis, 1 patient; neutropenia, 1 patient). A total of 6 patients (40%) underwent everolimus temporary discontinuation due to transient toxicity. No patient required definitive discontinuation due to AEs.
DISCUSSION
The present study shows that everolimus is active in progressive, advanced pNEC G3 tumors with well-or moderately differentiated morphology and Ki67 less than 55%.
To the best of our knowledge, only few single case reports have investigated the role of everolimus in pNEC G3, [17] [18] [19] and no series has been reported so far.
Data on treatment of NEC G3 tumors are, in general, scanty, because of the rarity of this subgroup of NEN, which accounts for only 7% of pNENs in the largest series of approximately 1000 patients reported by Rindi et al. 3 In these patients, both ENETS and the North American Neuroendocrine Tumor Society recommend to use platinum-based chemotherapy in combination with etoposide 6, 7 ; however, such recommendations are mainly based on few retrospective studies including heterogeneous populations, [27] [28] [29] which were published before the ENETS grading system was proposed 20 and validated as the strongest prognostic tool. 3 More recently, the Nordic group has highlighted, in the largest series of NEC G3 tumors ever published, 5 that it may not be correct to consider NEC G3 as a single entity. Furthermore, that study showed a lower response to platinum-based chemotherapy in tumors with Ki67 less than 55%, suggesting the possibility to plan alternative treatments in these patients. It was also noted that tumors arising from the pancreas had a higher probability to express somatostatin receptors and a relatively lower Ki67 in comparison with primary tumors arising from other digestive sites. 5 A recent large retrospective analysis has identified 3 different categories with different prognosis among NEC G3 that may be identified by combining tumor morphology (well-or poorly differentiated) and Ki67 cutoff level (20% or 55%). 30 Furthermore, the recently updated ENETS guidelines suggest to take into account tumor morphology when planning therapeutic approach of advanced pNEC G3. 31 Based on these considerations, the present study selected a homogeneous subgroup of patients with NEC G3 arising from the pancreas, Ki67 less than 55%, without a poorly differentiated morphology, who received everolimus during their clinical history. In this group of patients, a median PFS of 6 months and a median OS of 28 months were observed, a figure that is in general similar to that reported by using systemic chemotherapy. 8 In fact, previous studies have reported that the standard treatment of NEC G3 with cisplatin in combination with etoposide provided a median PFS between 4 and 9 months, whereas median OS ranged from 11 to 19 months. 8 As expected, the overall everolimus efficacy to induce disease stabilization in the setting of NEC G3 patients was lower in comparison with that observed in the RADIANT-3 trial conducted in well-or moderately differentiated pancreatic NENs, in which an 11-month median PFS was obtained.
14 However, a consistent proportion of patients evaluated in the present study (40%) reached a prolonged tumor stabilization of at least 12 months, a finding that is similar to the overall major results reported by the RADIANT-3 study.
14 This observation supports the hypothesis that NEC G3 group consists of heterogeneous diseases, which in some cases may have the same probability of response to everolimus treatment in comparison with well-or moderately differentiated NENs.
Interestingly, a sustained response to everolimus of at least 12 months was observed in 3 of 4 patients who received the treatment as first-line approach (12, 17, and 22 months), supporting the hypothesis of a major activity of this therapy in the early course of the disease, as previously reported in other groups of patients. 32, 33 As far as tolerability is concerned, a similar safety profile was observed in this study in comparison with both phase 3 trials and "real world" experience, 14, [33] [34] [35] thus confirming that everolimus may be considered a well-tolerated treatment even in the more aggressive subgroup of NEC G3 tumors, where more toxic systemic chemotherapies are commonly used as standard treatments.
In summary, the present study suggests that everolimus is active in a subgroup of patients with pNEC G3 without poorly differentiated morphology and with Ki67 less than 55%.
This finding, although deriving from a small number of patients analyzed with a retrospective approach, may represent the basis for a possible larger prospective study investigating the role of this drug in selected subgroups of pNECs. Currently, the role of everolimus in NEC G3 patients is under investigation in different settings: a randomized phase 2 trial 36 is evaluating its activity as maintenance therapy after response to first-line chemotherapy; the Evinec trial is enrolling NEC G3 patients to be treated with everolimus after failure of previous chemotherapy 37 ; and another phase 2 trial is investigating its efficacy in association with temozolomide as first-line approach in NEC G3 with Ki67 less than 55%. 38 All these studies aim to improve response rates and clinical benefit rates without increasing toxicity in this set of patients and could offer patients with pNEC G3 additional therapeutic options different from platinum-based chemotherapy, with promising clinical outcome and more acceptable toxicity profile. 
